Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.330
-0.010 (-0.43%)
At close: Mar 10, 2025, 4:00 PM
2.322
-0.008 (-0.35%)
After-hours: Mar 10, 2025, 7:39 PM EST
Protalix BioTherapeutics Revenue
Protalix BioTherapeutics had revenue of $17.96M in the quarter ending September 30, 2024, with 73.60% growth. This brings the company's revenue in the last twelve months to $45.67M, down -28.22% year-over-year. In the year 2023, Protalix BioTherapeutics had annual revenue of $65.49M with 37.48% growth.
Revenue (ttm)
$45.67M
Revenue Growth
-28.22%
P/S Ratio
3.73
Revenue / Employee
$219,553
Employees
208
Market Cap
171.57M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 65.49M | 17.86M | 37.48% |
Dec 31, 2022 | 47.64M | 9.29M | 24.22% |
Dec 31, 2021 | 38.35M | -24.55M | -39.03% |
Dec 31, 2020 | 62.90M | 8.21M | 15.00% |
Dec 31, 2019 | 54.69M | 20.45M | 59.73% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PLX News
- 1 day ago - Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025 - PRNewsWire
- 4 weeks ago - Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference - PRNewsWire
- 2 months ago - Protalix BioTherapeutics Issues 2025 Letter to Stockholders - PRNewsWire
- 3 months ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa - PRNewsWire
- 4 months ago - Protalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results - PRNewsWire
- 4 months ago - Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024 - PRNewsWire
- 4 months ago - Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024 - PRNewsWire